Bayer Competitors and Similar CompaniesClear all
Bayer's competitors and similar companies include Astellas Pharma, Novartis, Pfizer, GSK and Johnson & Johnson.
 Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Johnson & Johnson Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. | ||
Founding Date | Founding Date 1863 | Founding Date 1923 | Founding Date 1996 | Founding Date 1849 | Founding Date 2000 | Founding Date 1886 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations London, GB HQ Boumerdes, DZ Buenos Aires, AR Abbotsford, AU Wien, AT Wavre, BE Rio De Janeiro, BR see more | Locations New Brunswick, US HQ Buenos Aires, AR Sydney, AU Vienna, AT Minsk, BY Beerse, BE Sofia, BG see more | |
Employees | Employees 88,5021% decrease | Employees 14,754 | Employees 75,883 | Employees 81,0008% decrease | Employees 68,629 | Employees 138,1005% increase |
Valuation ($) | Valuation ($) 27.1 b | Valuation ($) 20.8 b | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) 862.5 m | Valuation ($) 396.3 b |
Financial | ||||||
Revenue (est.) | Revenue (est.) €45.6b (FY, 2025) | Revenue (est.) ¥2.1t (FY, 2026) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) £32.7b (FY, 2025) | Revenue (est.) $94.2b (FY, 2025) |
Cost of goods | Cost of goods €14b (FY, 2025) | Cost of goods ¥213.8b (FY, 2026) | Cost of goods $8.4b (FY, 2025) | Cost of goods $16.1b (FY, 2025) | Cost of goods £5.6b (FY, 2025) | Cost of goods $30.3b (FY, 2025) |
Gross profit | Gross profit €32.5b (FY, 2025) | Gross profit ¥2t (FY, 2026) | Gross profit $49.8b (FY, 2025) | Gross profit $46.5b (FY, 2025) | Gross profit £28.5b (FY, 2025) | Gross profit $63.9b (FY, 2025) |
Net income | Net income (€3.6b) (FY, 2025) | Net income ¥291.6b (FY, 2026) | Net income $14b (FY, 2025) | Net income $7.8b (FY, 2025) | Net income £6.3b (FY, 2025) | Net income $26.8b (FY, 2025) |
Operating ⚠ | ||||||
Countries | Countries 83 (FY, 2021) | Countries N/A | Countries N/A | Countries 200 (FY, 2024) | Countries 92 (FY, 2021) | Countries N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 51 (FY, 2024) | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 27 (FY, 2024) | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 5 (FY, 2024) | Registration Phase Products N/A | Registration Phase Products N/A |
Suppliers | Suppliers 93.8 k (FY, 2021) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 37.5 k (FY, 2021) | Suppliers N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 3.5b | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Astellas Pharma
HQ
Tokyo, JP
Employees
14,754
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyPfizer
HQ
New York, US
Employees
81,000↓ 8% decrease
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View companyGSK
HQ
London, GB
Employees
68,629
GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products.
View company